Abelacimab - CISMeF

Preferred Label : Abelacimab;

NCIt definition : A human anti-factor XI (FXI) monoclonal antibody, with potential anti-thrombotic activity. Upon administration, abelacimab targets and binds to the catalytic domain of FXI, thereby inactivating FXI, and also inhibits the activated form of FXI factor XIa. This prevents the activation of factor XIIa (FXIIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.;

UNII : KX1N4TV7UY;

CAS number : 2098724-83-3;

Molecule name : MAA 868; MAA-868;

NCI Metathesaurus CUI : CL1382261;

Détails

Origin ID

C169755;

UMLS CUI

C5421260;

Currated CISMeF NLP mapping
- Abelacimab [SMS substance]
- abelacimab [MeSH concept]
- abelacimab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- abelacimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients